CHMP recommends approval of satralizumab for neuromyelitis optica spectrum disorder

Approval of this humanised monoclonal antibody inhibitor of interleukin-6 receptor activity for adults and adolescents >12 years of age as a monotherapy or in combination with immunosuppressive therapy, is based on data from the SAkuraStar and SAkuraSky studies.

Source:

European Medicines Agency